A Study to Test the Safety and Tolerability of Long-term UCB0107 Administration in Study Participants With Progressive Supranuclear Palsy

You might be able to join this study if you have already been diagnosed with Progressive Supranuclear Palsy (PSP), specifically a type called Richardson's Syndrome. A key requirement is that you must have previously participated in a specific earlier study, called PSP003 (NCT04185415), and completed the treatment part of that study.

Anyone, male or female, aged 40 or over can be considered. If you are a woman who could become pregnant, or a man, you would need to agree to use effective birth control methods during the study and for some months after the last dose of the study medicine to prevent pregnancy.

You cannot join if you had to stop the previous PSP003 study for certain safety reasons, or if you had serious thoughts of harming yourself during the PSP003 study. However, even if you did have suicidal thoughts, the study doctors might still consider you if a mental health expert believes it's safe for you to participate.

If you decide to take part, the main purpose is to monitor your health and how your body responds to the study medicine, UCB0107, over a longer period. Since you've already been part of the previous PSP003 study, you'll be continuing your involvement, and the research team will explain exactly what this new, longer-term study will involve for you.

You will have regular visits to the clinic where the study team will carry out various assessments. These will likely include physical examinations, blood tests, and possibly other tests to check your overall health and how the medicine is affecting you. You will also continue to receive doses of UCB0107 as planned by the study doctors.

The research team will provide you with a detailed plan of visits and assessments. The total duration of your participation will depend on the study design and your individual response, and they will explain this clearly before you make any decision.